Gba1 Mutant Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GBA1 mutations represent the most significant genetic risk factor for Parkinson's disease. GBA1 encodes glucocerebrosidase (GCase), a lysosomal enzyme whose deficiency leads to accumulation of glucocerebroside and impaired autophagy, creating a pro-neurodegenerative cellular environment.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Encodes glucocerebrosidase (GCase)
- Catalyzes glucosylceramide breakdown in lysosomes
- Essential for sphingolipid metabolism
- Maintains lysosomal function
- Severe mutations (null): Cause Gaucher disease
- Mild mutations (reduced activity): Increase PD risk 5-20x
- Common risk variants: N370S, L444P, E326K
- Reduced GCase activity
- Lysosomal dysfunction
- Impaired autophagy
- α-Synuclein accumulation
- Increased glucocerebroside levels
- Enlarged lysosomes
- Reduced cathepsin activity
- Impaired protein degradation
- Autophagosome accumulation
- Increased α-synuclein aggregation
- Enhanced exosomal α-synuclein secretion
- Reduced cellular clearance
- Propagation to neighboring neurons
- Increased oxidative stress
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
- Neuroinflammation
- Earlier onset (5-10 years earlier)
- More severe cognitive decline
- Higher prevalence of hallucinations
- Faster progression
- Less levodopa response
- Diffuse Lewy body disease pattern
- Severe cortical involvement
- Rapid cognitive decline
- Patient-derived iPSC neurons (heterozygous)
- GBA1 knockout dopaminergic neurons
- CRISPR-corrected isogenic lines
- Gaucher disease patient neurons
- Reduced GCase activity
- Elevated glucosylceramide
- Increased β-glucocerebrosidase
- Lysosomal impairment indicators
- Ambroxol (GCase enhancer)
- Small molecule chaperones
- Gene therapy approaches
- Autophagy enhancers
- TFEB activators
- Lysosomal regeneration
The study of Gba1 Mutant Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neumann et al., GBA mutations in Parkinson disease and atypical parkinsonism (2009)
- Mazzulli et al., Gaucher disease glucocerebrosidase and α-synuclein form a pathogenic complex (2011)
- Schapira & Gegg, Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease (2011)
- Bennett & Boya, The relationship between GBA deficiency and the pathogenesis of Parkinson's disease (2020)